Introduction {#Sec1}
============

Malaria occurs in 109 countries with 3.3 billion people at risk of contracting the disease; 247 million cases of malaria are reported annually \[[@CR1]\]. The World Health Organisation (WHO) recommends replacing monotherapies with artemisinin combination therapies (ACTs) \[[@CR2]\]. According to official figures, 49 million ACT courses were distributed in 2006, but real usage is likely to be much higher \[[@CR1]\].

Artesunate (AS) combined with amodiaquine (AQ) is currently one of the most widely used ACTs and has been adopted by 20 countries worldwide (19 in Africa) as the first line treatment for malaria. Both AS and AQ are currently administered as a loose formulation or in co-blister packs; however, due the large number of tablets involved, there is a possibility of patients failing to adhere to their treatment regimen or complete their course of therapy. To overcome this, a fixed-dose combination treatment (AS/AQ) that provides a simplified regimen has been developed and registered.

Artesunate and AQ have independent but complementary modes of action: the former is a short-lived, highly potent artemisinin that provides a rapid reduction of parasite biomass, whereas the latter has a longer half-life to ensure the eradication of residual parasites \[[@CR3]\]. Artesunate \[dihydroartemisinin-10α-hemisuccinate, molecular weight (MW) 384\] is considered to be a prodrug, as it is rapidly and extensively converted via chemical and enzymatic pathways to its main bioactive metabolite, dihydroartemisinin (DHA; also referred to as artenimol, MW 284). Following oral intake, AS levels are transient, and DHA is the predominant species; the two moieties are roughly equipotent \[[@CR4]\], and both contribute to parasite killing. The pharmacology of AS and DHA, following oral administration of AS, show considerable inter-individual variation and are affected by disease status \[[@CR5], [@CR6]\]. The elimination half-life (t~½~) of DHA averages 0.65--2.59 h \[[@CR7], [@CR8]\]. Amodiaquine is also considered to be a prodrug and is rapidly and extensively converted to its main metabolite, *N*-desethylamodiaquine (DEAQ), essentially in the liver by cytochrome P 2C8 (CYP2C8) \[[@CR9]\]. Unlike AS, AQ has a negligible effect on parasites. In adults, the elimination half-life of AQ is approximately 4 h \[[@CR10]\], but DEAQ has a much longer but variable half-life (2.5--18.2 days) \[[@CR11], [@CR12]\].

The pharmacology of oral AS, often co-administrated with mefloquine, has been studied in both healthy volunteers and malaria patients. In contrast, despite years of widespread use either alone or combined with AS, pharmacological information on AQ is inadequate.

The aim of this study was to investigate the pharmacokinetic properties, tolerability, and bioavailability of AS and AQ when co-administered as either fixed or non-fixed products in healthy normal volunteers.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was an open, randomised, two-period crossover trial in which the PK properties, tolerability and bioavailability of AS + AQ when administered as a fixed-dose or non-fixed dose preparation were compared. The study was conducted in accordance with international Good Clinical Practice standards and monitored. The protocol was approved by the Institution Ethical Review Board of the Teaching Hospital Universiti Sains Malaysia, Kota Bharu, Malaysia and the WHO Ethics Committee, and was authorised by the Malaysian Ministry of Health.

A total of 24 healthy normal volunteers (HNVs), aged between 21 and 45 years, were randomised to receive either the non-fixed (NF) or the fixed (F) combination regimen during Study Period 1. The randomisation process was carried out by using a table of random numbers to select 24 consecutive, unduplicated numbers between 01 and 24. After a wash-out period of 60 days (5 × t~½~ DEAQ 45--90 days), subjects entered Study Period 2 and were given the alternative treatment combination. Thus, one group of subjects received the fixed, followed by the non-fixed combination (F--NF), while the other group received the non-fixed, followed by the fixed product (NF--F).

Drugs were administered under fasting conditions. Each subject received a single total dose of 200 mg AS plus 540 mg AQ when given the fixed product, and 200 mg AS plus 612 mg AQ with the non-fixed product. These doses represent 1 day of a 3-day therapeutic course and were selected to be as close as possible to the target treatment doses of 4 and 10 mg kg^−1^ day^−1^ for AS and AQ, respectively. The doses of AQ in the fixed and non-fixed formulations were different because of the different strengths of the formulations used.

Study drugs {#Sec4}
-----------

The fixed-dose co-formulated product (manufactured by Creapharm, France, batch no. CPM 5856) consisted of 100 mg AS and 270 mg AQ base; the loose non-fixed product consisted of AS (Arsumax 50 mg tablets; Sanofi-Aventis, Paris, France/Guilin Pharma Co, China, batch no. 31201) and AQ (Flavoquin 153 mg of AQ base; Hoechst Marion Roussel, Sanofi-Aventis, batch no. 4).

Entry criteria {#Sec5}
--------------

Volunteers were recruited by means of advertisements placed at the teaching hospital of the Universiti Sains Malaysia, Kota Bahru. Written informed consent was required before the volunteers were allowed to participate in the trials. Entry criteria included a negative pregnancy test for women; a negative malaria thick smear; no significant abnormal findings on the medical history or clinical examination (including electrocardiogram, haematology, liver and renal function tests); no history of antimalarial treatment in the preceding 2 months; no other drugs or medications in the preceding week; adequate venous access; no abuse of alcohol or recreational drugs; no known allergy to the study drugs; smokers (\>10/day) were also excluded.

Drug assay {#Sec6}
----------

### Sampling {#Sec7}

Blood samples were collected at pre-dose, at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h post-medication and at 5, 7, 14, 21, 28, 35, 42 and 60 days post-medication. Day 60 for Study Period 1 and Day 0 for Study Period 2 coincided. Specimens in the first 12 h of each study period were drawn via an indwelling catheter; for the remaining periods, blood samples were drawn by direct venipuncture. Blood samples (5 ml each) were stored in heparinised vacutainer tubes for further processing. The levels of AQ and DEAQ were measured at all time points, while those of AS and DHA were measured at pre-dose and at 0.25, 0.50, 0.75, 1.0, 1.5, 2, 3, 4, 6, 8 and 12 h after drug administration. After centrifugation of blood samples, the plasma samples were immediately transferred to separate, appropriately labelled plastic cryotubes and frozen at −70°C.

### Analytical methods {#Sec8}

The assays were carried out at the Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia.

**Artesunate and dihydroartemisinin** This assay method was validated with minor modifications of a previously published method \[[@CR13]\]. The analyses of AS and DHA were carried out on BAS 200A high-performance liquid chromatography/electrochemical (HPLC--EC; BAS, West Lafayette, IN) systems operating at reductive mode. Chromatographic separation of AS, DHA and the internal standard artemisinin (QHS) was obtained at room temperature (25°C) on an Inertsil C4 column (internal diameter 150 ×  4.6 mm , particle size 5 μm; GL Sciences, Tokyo, Japan). The mobile phase consisted of acetonitrile (ACN) and 0.05 *M* acetic acid (40:60 %v/v) adjusted to pH 4.0 with 1 *M* NaOH. The flow rate was 1.50 ml/min. Detection was performed in the reductive mode at −1000 mV in an oxygen-free environment. The HPLC-EC (reductive) system produced a linear response for the concentration of AS and DHA varying from 20 to 1600 ng/ml respectively. The extraction recoveries of AS, DHA and QHS were above 79% with a coefficient of variation (CV) not exceeding 13%. The lower limit of quantification (LLOQ) of AS was 20 ng/ml, and its accuracy and CV were −0.1 and 4.4%, respectively; the corresponding values for DHA (LLOQ 20 ng/ ml) were −2.6 and 6.0%, respectively. The within-day and day-to-day precision for both AS and DHA at low, medium and high concentrations did not exceed 15%.

**Amodiaquine and *N*-desethylamodiaquine** The analyses of AQ and DEAQ were carried out on BAS 200A HPLC--EC systems coupled to an EC detector operating at oxidative mode. The analysis of AQ, DEAQ and the IB-DEAQ (internal standard) was carried out at room temperature (25°C) using an Inertsil C4 column (internal diameter 150 ×  4.6 mm, particle size 5 μm; GL Sciences). The mobile phase consisted of ACN and 0.05 *M* KH~2~PO~4~ (11:89, %v/v) adjusted to pH 4.0 with orthophosphoric acid. The flow rate was 1.0 ml/min. Detection was performed in the oxidative mode at +800 mV. The extraction recoveries of AQ, DEAQ and IB-DEAQ were all above 80%, with a CV of less than 11%. The HPLC--EC (oxidative) system produced a linear response for the concentration of AQ and DEAQ that varied from 20 to 1600 ng/ml, respectively. The LLOQ of AQ and DEAQ were 20 ng/ml, and the accuracy and variation were of 4.2 and 5.0%, respectively; the CV were 7.5 and 7.3%, respectively. The within-day and day-to-day precision for both AQ and DEAQ were less than 15%.

Pharmacokinetic analyses {#Sec9}
------------------------

We measured the parent drug and main active metabolite of both compounds (AS + DHA and AQ + DEAQ). In addition, the total DHA concentration was estimated by summation of HPLC-determined DHA and DHA equivalence of the corresponding plasma sampling times of AS for each individual. The DHA equivalence was determined by converting the drug concentration of AS to DHA stoichiometrically. The pharmacokinetic parameters C~max~, T~max~, and AUC~0-t~ were determined using model independent formulae \[[@CR14]\]. Maximum achieved concentration (C~max~) and time to achieve the maximum concentration (T~max~) were obtained from a visual inspection of the plasma concentration versus time curve. Area under the concentration--time curve from 0 to t (AUC~0-t~, where t = last quantifiable drug concentration) was calculated using the linear trapezoidal rule: AUC~0-t~ = \[(C~1~ + C~2~)/2(t~2~ - t~1~)\] + ..... + \[(C~n--1~ + C~n~)/2 (t~n~ - t~n--1~)\]. The AUC~0-∞~ (up to infinity) was calculated by the formula AUC~0-t~ + Ct /λz where Ct is the concentration at the last quantifiable time. From the terminal log-linear (disposition) phase, a first order elimination rate constant (λz) was estimated by linear regression and terminal half-life value (t~½~) was estimated from at least three concentration values using the equation (t~½~) = ln2 / λz. The mean residence time (MRT) was calculated for both parent compounds and metabolites as the AUMC/AUC where AUMC is the area under the first moment-versus-time curve.

Bioavailability {#Sec10}
---------------

For bioequivalence studies, the 1992 Federal Drug Agency (FDA) guidance recommends that the statistical analysis for pharmacokinetic measures, such as AUC and C~max~, be based on the two one-sided tests procedure that examines whether the average values for the pharmacokinetic measures determined after administration of the test and reference products were comparable. This approach is termed average bioequivalence and involves the calculation of a 90% confidence interval (CI) for the ratio of the averages (population geometric means) of the measures for the test and reference products. To establish bioequivalence, the calculated confidence interval should fall within a limit, usually between 80 and 125%, for the ratio of the product averages \[[@CR16]\]. This method is equivalent to the corresponding two one-sided tests procedure with the null hypothesis of bioinequivalence at the 5% significance level \[[@CR17]\].

Bioavailabilities of the fixed and non-fixed AS/AQ formulations were compared using mean AUC~0-t~. In addition, we tested the C~max~, t~max~ and t~½~. Differences in the ln mean AUC~0-t~ and ln mean C~max~ between treatment periods were compared using analysis of variance (ANOVA). The model allowed for the effects of formulation, period, sequence and subjects within sequence on the observed parameter.

For AUC~0-t~ and C~max~, we applied the Schuirmann's two one-sided tests (TOST) to compute the probability to reject the null hypothesis (i.e. that the two products are different). The T~max~ and t~½~ values were compared by the Wilcoxon signed rank test. All statistical analyses were performed with the statistical software package EquivTest ver. 2.0 \[[@CR15]\].

Safety {#Sec11}
------

We used standard definitions for adverse events (AEs) and serious adverse events (SAEs). All subjects were assessed clinically at baseline. Reporting of symptoms was solicited during the course of the study. Clinical AEs were described by the attending physician in terms of signs and symptoms and classed by body system: gastrointestinal (GI), cardiovascular (CVS), central nervous system (CNS), etc. They were assessed for severity \[mild (Grade 1), moderate (Grade 2), severe (Grade 3), very severe (Grade 4)\] using the Common Toxicity Criteria (CTC V3.0; National Institute of Health, Bethesda, MD).

Laboratory examinations (haematology, liver and renal functions) were conducted at Day 0, Day 7 and Day 28 of each study period. Twelve lead electrocardiograms (ECGs) were performed at baseline and at 1, 2, 4, and 24 h post-drug administration; this was repeated for Study Period 2 (results to be reported in a separate analysis). All AEs that occurred during the study were recorded with the date and time of occurrence and the date the abnormal finding disappeared.

The chi-squared test was used to compare the frequencies of: (1) AEs between groups and (2) normal/abnormal laboratory values in shift tables. The Cochran--Mantel--Haentzel statistic was used to assess the general association of the treatment groups and the occurrence of at least one AE in a subject during the two study periods.

Results {#Sec12}
=======

Disposition and baseline characteristics {#Sec13}
----------------------------------------

Study subject disposition is shown in Fig. [1](#Fig1){ref-type="fig"}. Two subjects were excluded from the overall data analysis: one subject received only the non-fixed AS/AQ combination in Study Period 1, but was later withdrawn from the study because of acute gouty arthritis (this event was a recrudescence of prior disease that was judged to be probably related to the study drug); the other subject had an extraordinarily high DEAQ AUC~0-t~ (approx. ten10-fold higher than that with the fixed combination) after having received the non-fixed combination. This observation was deemed to be an unexplainable outlying result, and all pharmacokinetic data pertaining to this subject were excluded from the analyses. The threshold for outliers was calculated as recommended for skewed distributions from the interquartile range. Inclusion of this subject's data in the analyses did not alter any bioequivalence conclusions (data not shown). Therefore, 23 of the original 24 subjects were analysed for drug disposition (six males, 17 females) and 22 for comparative bioavailability.

The mean age of the subjects was 27.3 ± 6.8 years. Medical history and vital signs were similar in the two groups except pulse rate (*p* = 0.02). Fig. 1Profile of study subject disposition

Pharmacokinetics {#Sec14}
----------------

After oral administration, AS and AQ were rapidly absorbed and underwent rapid and extensive metabolism to their respective metabolites, DHA and DEAQ. The plasma levels of both DHA and DEAQ were manifold higher and persisted for longer than their respective parent compounds. The pharmacokinetic properties of AS, DHA, AQ, DEAQ and total DHA are given in Table [1](#Tab1){ref-type="table"}; the plasma time--concentration profiles of AS, DHA, AQ and DEAQ are shown in Fig. [2](#Fig2){ref-type="fig"}. Table 1Main pharmacokinetic measures associated with the co-administration of artesunate and amodiaquine as a fixed and non-fixed combination, respectivelyCompound (mean ± SD)ProductC~max~ (ng/ml)T~max~ (h)AUC~0-t~ (ng h/ml)AUC~0-∞~ (ng h/ml)AUC~t-∞~ (ng/h/ml)Extra (%)T~½~ (h)MRT (h)Artesunate (AS)Fixed333 ± 2330.26 ± 0.05201.5 ± 133.4213.2 ± 139.834.2 ± 25.117.8 ± 11.30.63 ± 0.550.94 ± 0.57Non-fixed444 ± 4250.53 ± 0.39238.5 ± 199.2391.1 ± 247.248.6 ± 29.116.5 ± 11.40.76 ± 0.61.05 ± 0.72Dihydroartemisinin (DHA)Fixed609.8 ± 282.80.56 ± 0.391,369.4 ± 564.21,468.9 ± 579.999.6 ± 63.87.4 ± 4.81.68 ± 0.912.6 ± 1.0Non-fixed874.5 ± 621.51.05 ± 0.951,540.6 ± 643.41,656.0 ± 678.976.9 ± 37.24.9 ± 2.11.42 ± 0.652.3 ± 0.7Total dihydroartemisinin equivalentsFixed802.4 ± 424.70.5 ± 0.41,522.1 ± 633.51,706.6 ± 637.587.2 ± 43.45.7 ± 3.51.7 ± 0.9-Non-fixed1077.5 ± 825.41.0 ± 1.01,664 ± 767.21,801.4 ± 789.077.9 ± 43.84.8 ± 2.41.3 ± 0.7-Amodiaquine (AQ)Fixed59.4 ± 42.30.89 ± 0.4106.6 ± 65.2215.6 ± 172.095.67 ± 106.240.1 ± 16.82.3 ± 1.43.62 ± 1.82Non-fixed61.7 ± 24.81.44 ± 1.1141.1 ± 100.5226.1 ± 75.274.2 ± 41.931.2 ± 8.72.2 ± 1.13.64 ± 1.76Desethylamodiaquine (DEAQ)Fixed879 ± 6341.39 ± 0.830,021 ± 14,21163,499 ± 75,73213,378 ± 13,30327.2 ± 16.6201 ± 119260.3 ± 161.0Non-fixed973 ± 5111.7 ± 0.7738,045 ± 19,69650,287 ± 25,66610,462 ± 6,40122.0 ± 12.0224 ± 102259.6 ± 151.7MRT, Mean residence time; SD, standard deviationData are presented as the mean ± SD of non-normalised dataSee the [Methods](#Sec2){ref-type="sec"} section, subsection [Bioavailablity](#Sec10){ref-type="sec"} for definition of pharmacokinetic measuresFig. 2Concentration--time profiles of artesunate (*AS*)/dihydroartemisinin (*DHA*) (**a**) and amodiaquine (*AQ*)/desethylamodiaquine (*DEAZ*) (**b**). *Filled diamonds* Fixed product, *open boxes* non-fixed product

The relative bioavailabilities of total DHA and DEAQ expressed as AUC~0-t~ produced by the fixed product were similar to those of the non-fixed product (F:NF ratios 102.3 and 107%, respectively). The analysis of comparative bioavailability of the two products is shown in Table [2](#Tab2){ref-type="table"}. There was no evidence of carry-over effects between subjects except for the AQ (parent) AUC, no period effect except for total DHA AUC and no drug effects within subjects between the two formulations except a marginal effect for AQ and DEQA AUC. For both total DHA and DEAQ, the AUC~0-t~ values obtained with the fixed combination lie within the 95% CI of the non-fixed products \[data not shown: provided as Electronic Supplementary Material ([ESM](#N0x1ce6990N0x2d8bd78){ref-type="supplementary-material"})\]. The values produced by the fixed product appear to be tighter than those provided by the non-fixed product for both total DHA and DEAQ (data not shown: provided as [ESM](#N0x1ce6990N0x2d8bd78){ref-type="supplementary-material"}). Table 2Comparative bioavailabilities of fixed and non-fixed combinations of artesunate and amodiaquine. Combinations are measured as total DHA and DEAQCompoundPharmacokinetic measureANOVAGLSMSchuirmann TOST L/U *p*-valueCarry-overPeriodDrugCV (%)FixedNon-fixedRatio90%CITotal DHAAUC~0-t~(ng h/ml)0.560.020.384.311398.31522.20.90.79, 1.080.08/0.002C~max~ (ng/ml)0.630.230.288.7714.8870.40.80.60, 1.120.44/0.01T~max~^a^ (h)0.531.030.510.03 (Wilcoxon)T~½~ (h)0.780.930.13130.561.491.251.190.98, 1.450.002/0.34ASAU~C0-t~ (ng h/ml)0.530.120.638.85168.04182.40.920.72, 1.170.17/0.0224C~max~ (ng/ml)0.460.190.9111.89281.08291.960.960.67, 1.380.1923/0.1123T~max~^a^ (h)0.260.550.470.005 (Wilcoxon)T~½~(h)0.470.800.75−175.120.480.590.810.27, 2.380.49/0.23DHAAUC~0-t~ (ng h/ml)0.850.070.248.511257.121430.970.8780.73, 1.060.198/0.0019C~max~ (ng/ml)0.970.140.108.70550.35736.520.740.56, 1.000.6542/0.0032T~max~^a^ (h)0.561.070.520.06 (Wilcoxon)T~½~ (h)0.930.780.29102.141.471.321.110.94, 1.310.002/0.11AQAUC~0-t~(ng h/ml)0.030.430.0415\*8.6097.34136.750.710.54, 0.940.761/0.0018C~max~ (ng/ml)0.060.740.288.8753.8963.690.850.71, 1.030.26/0.0012T~max~^a^ (h)0.851.620.520.04 (Wilcoxon)T~½~ (h)0.640.340.1641.621.422.600.550.24, 1.240.85/0.05DEAQAUC~0-t~(ng h/ml)0.630.450.053.6426630350000.80.6, 0.90.65/0.0003C~max~(ng/ml)0.450.10.175.32749.1872.70.90.7, 1.00.26/0.001T~max~ (h)1.391.680.830.14 (Wilcoxon)T~½~ (h)0.080.920.6014.46159.03188.090.840.49, 1.450.43/0.11GLSM, Geometric least squares mean; CI, confidence interval; CV, coefficient of varianceNumbers under carry-over, period and drug are *p* values. Values in the Fixed and Non-fixed columns are means^a^Comparison by arithmetic means and Wilcoxon test (non-parametric approach)

Based on the 90% CI of the geometric least squares means ratios (GLSMR), the C~max~ and AUC~0-t~ values produced with the fixed combination with respect to the non-fixed combination were within the upper boundary (125%) but extended beyond the lower boundary (80%) of the confidence interval for all moieties except AS C~max~, which was also \>125% (Table [2](#Tab2){ref-type="table"}). The Shuirmann TOST was non-significant for lower limits, while the upper limits of the one-tailed *t*-statistics were significant (again except for AS C~max~) (Table [2](#Tab2){ref-type="table"}). Plasma C~max~ and AUC~0-t~ of total DHA were lower in the fixed combination by 12 and 8%, respectively, for total DHA and by 15 and 14%, respectively, for DEAQ. The T~max~ was significantly shorter in subjects given the fixed product for total DHA, AS and DHA, longer for AQ and not different for DEAQ (Table [2](#Tab2){ref-type="table"}). The within-subject variation (% CV) of the AUC~0-t~ between the non-fixed and the fixed combination were 4.3% for total DHA and 3.6% for DEAQ. The t~½~ for both formulations was not bioequivalent (Table [2](#Tab2){ref-type="table"}).

Mean residence times (see Table [1](#Tab1){ref-type="table"}) were compared between the fixed and non-fixed combination for AS, DHA, AQ and DEAQ using a *t* test. The comparisons were found to be non-significant. The mean ± standard deviation AUC ratios AS:DHA were 0.08 ± 0.12 and 0.09 ± 0.06 for the fixed and non-fixed product, respectively; the corresponding values for AQ:DEAQ were 0.002 ± 0.002 and 0.003 ± 0.004, respectively, with no difference between the two formulations.

When individual subjects were considered, there was no consistent direction of change in any parameter measured. Figure [3](#Fig3){ref-type="fig"} depicts individual data with the two products of AUC~0-t~ for total DHA and DEAQ. The ranges of values were similar for the fixed and non-fixed combination, and changes went both ways between the two combinations: for DHA and DEAQ, values increased in 46 and 35% of patients, respectively, and decreased in 54 and 65%, respectively. Fig. 3Stick plots of the area under the concentration--time curve from time zero to last quantifiable measurement (AUC~0-t~) of total DHA (**a**), AS (**b**), DHA (**c**), AQ (**d**) and DEAQ (**e**) of the fixed versus non-fixed products for individual subjects (*numbers*)

Safety {#Sec15}
------

Both formulations were tolerated. Overall, 42 events were reported. During Study Periods 1 and 2, 45 and 55% of subjects had at least one AE. By drug group, the proportions were: (1) 67 (F) versus 36% (NF) in Study Period 1, and (2) 45 (F) versus 58% (NF) in Study Period 2.

There was no statistically significant difference between sequences (62 and 41% of subjects in the F--NF and NF--F sequences had at least one AE, *p* = 0.14) or between Study Period 1 and 2 (*p* = 1.0). The Cochran--Mantel--Haentzel statistic for a general association of the treatment groups and the occurrence of at least one AE in a subject during the two periods of the study showed no significant difference (*p* = 0.56)

The most common AEs were liver enzyme abnormalities (21% of all AEs), flushing (17%), dizziness and giddiness (14% each) and nausea (7%); all other events contributed \<5%. The body systems most commonly affected were the gastro-intestinal system (35% of AEs including liver enzyme abnormalities) and the central and peripheral nervous system (30% of all AEs).

There was no significant difference in the drug--event relationship between the two groups: 10/23 events in Group 1 and 13/20 in Group 2 were judged to be probably or definitely related to study drug (43 and 65%, respectively).

The main laboratory parameters monitored during the study are presented in Table [3](#Tab3){ref-type="table"}. At screening, 18 subjects had mildly abnormal laboratory values (Grade 1) and one subject exhibited a Grade 2 alanine transaminase (ALT) concentration. Pre-treatment, there was one case of Grade 1 neutropaenia (1600 × 10^6^/l) in the group that received the non-fixed combination first; this subject returned to normal by Day 7 of Study Period 1. One subject was inadvertently enrolled with a Grade 2 baseline value of ALT; this also normalised during follow-up. Table 3Laboratory parameter measures by product over timeLaboratory parametersProductBaselineDay 8Day 29Day 60MeanSDMeanSDMeanSDMeanSDRed rood cells (×10E12/l)F4.80.34.90.44.90.44.90.4NF4.90.34.90.450.44.90.3Haemoglobin (g/l)F14.1114.21.2141.114.11.1NF14.21.114.21.114.3114.11.2Haematocrit (%)F41.23.541.53.341.53.141.63.2NF41.82.641.53.242341.73.2Platelets (×10E9/l)F29942318.271.6303.972.1317.479.2NF304.184.7314.368.5294.968.2315.379.2White Blood Cells (×10E9/l)F6.71.36.82.16.81.271.8NF6.51.26.91.66.61.66.61.4Neutrophils (×10E9/l)F3.70.93.71.83.713.91.3NF3.51.13.91.33.61.43.50.9Alanine transaminase (U/l)F30.726.634.432.532.834.829.731.8NF22.519.219.512.620.710.531.721.3Aspartic transaminase (U/l)F28.912.127.511.227.713.226.313.7NF22.39.32513.322.84.926.710.2Alkaline phosphatase (U/l)F80.112.179.117.174.717.974.715.2NF69.514.470.715.775.71575.615.5Calcium (nmol/l)F2.40.12.40.22.40.12.50.1NF2.40.12.40.12.50.12.40.1Potassium (nmol/l)F40.44.10.44.10.34.10.3NF40.44.30.640.24.10.3Sodium (nmol/l)F140.72.7136.51.8137.92.1141.71.6NF139.62.7137.23.6137.82.3141.11.7Uric acid (mmol/l)F361.864.6361.874.6357.480.5345.153.7NF352.246353.956.4358.455.1347.854.1Creatinine (mmol/l)F104.513.1107.413.1102.211.4103.312.2NF102.312.599.910.1103.911.2104.612.6NF, Non-fixed combination; F, fixed combination

Four subjects presented five abnormal laboratory values during the study: three were Grade 3 and two were Grade 4. One subject with a baseline uric acid value of 546 μmoll/l experienced two episodes of Grade 4 (uric acid \> 590 μmoll/l) elevation in uric acid at Day 7 and 29 of Study Period 1, with values of 598 μmoll/l and 636 μmoll/l, respectively. This patient had a history of gout arthritis and was withdrawn from the study after Study Period 1.

Three individuals had one Grade 3 deviation each: (1) ALT = 156 U/L (5--20 × upper normal limit) at Day 60 of Study Period 2 (sequence NF--F); (2) hypocalcaemia calcium = 1.67 mmol/l (1.5--1.75 × upper limit) (sequence NF--F); (3) hyponatraemia sodium = 124 mmol/l (120--130 × upper limit) at Day 7 of Study Period 1. No volunteers developed neutropaenia during follow-up.

No serious AEs occurred. One subject was withdrawn due to an exacerbation of pre-existing gout which had not been declared or detected on recruitment. The subject was treated with non-steroidal anti-inflammatory drugs and ultimately recovered.

Discussion {#Sec16}
==========

The results of this study on adult Malaysian healthy volunteers using a cross-over design shows that AS and AQ are readily absorbed and well tolerated when co-administered either as loose products (in a non-fixed combination) or as a fixed-dose combination. However, the two combinations cannot strictly be defined as \"bioequivalent\".

We measured and reported the disposition of the parent compounds and their metabolites separately, but we considered the primary analytes (total DHA for AS, and DEAQ for AQ), as the biologically and clinically relevant indicators of drug absorption. For AS and DHA, the reason for combining the two measurements (after stoichiometrical conversion of the measured AS values) is that the two compounds have comparable antimalarial potencies \[[@CR4]\] and conversion of AS to DHA is rapid (chemical hydrolysis starts in the stomach). This makes their pharmacological effects indistinguishable over their very short residence time. This approach is supported by the correlation between the bioassay and the measurement of the two separate products \[[@CR18]\], the combined measurement may be the better parameter to use for pharmacokinetic--pharmacodynamic analyses. Although AQ is more potent in vitro than its metabolite, the systemic exposure to AQ is considerably lower than that to DEAQ \[[@CR10], [@CR12]\], which is solely responsible for sustained antimalarial activity after AS/DHA have been eliminated. The ratio between the AUCs of AS to DHA and AQ to DEAQ was approximately 8.5% and 0.02%, respectively; the AQ t~½~was one tenth of that for DEAQ.

In this study we used different descriptive and statistical approaches to assess and compare the product bioavailabilities, and these generally gave consistent results. It is commonly accepted that the two primary parameters used for measuring the extent of drug absorption are area under the curve (AUC) and maximum concentration (C~max~), both logarithmically transformed. To confirm bioequivalence of the two products, the geometric mean ratios (plus 90% CI) of these metrics should lie within an 80--125% window of acceptance \[[@CR16]\]. We used the ANOVA *F* test to identify the source of variance, be it a product, subject or period effect. It is important to appreciate that the tested hypothesis is stated as the "alternative" hypothesis; the null hypothesis is rejected in favour of the alternative hypothesis if there is sufficient statistical evidence against the null hypothesis. With the Schuirmann two one-sided tests, this is broken down into two one-sided hypotheses (above and below the allowed range), and two separate *t* tests are applied. For two products to be considered bioequivalent, the null hypothesis of bioinequivalence must be rejected (the test must be significant, normally with α = 0.05).

In general, the metrics we obtained with the fixed combination were well within the variance of the non-fixed combination. However, the strict criteria of bioequivalence were not met entirely. The mean geometric mean ratios for the AUCs obtained with the fixed versus non-fixed were 92 and 86% for total DHA and DEAQ, respectively; when the individual subjects' AUC were compared, the corresponding mean values were 102 and 107%, respectively. The 90% CI around the geometric least squares means ratios of the AUC with the fixed product over the non-fixed formulation were within the upper bound, but below the lower bound (78 and 62% for total DHA and DEAQ, respectively). The two products generated similar AS/DHA and AQ/DEAQ plasma--time profiles, but inter-subject variability, as expected, was wide, and this may have affected our interpretation of the results.

Despite not meeting the defined criteria for bioequivalence, certain elements indicate that the two formulations do behave in a similar way: no significant difference was seen in the AUC ratios (AS:DHA and AQ:DEAQ) or the MRT of the individual parent compounds and metabolites between the fixed and non-fixed formulation. The AUC above the inhibitory concentration is conceivably the best predictor of antimalarial efficacy for both a drug with a long residence time such as AQ/DEAQ, and short-lived drugs, such as AS/DHA, while C~max~ versus inhibitory concentration may also be of some value for the latter. Here, the C~max~ of total DHA obtained with a single 200 mg dose was 802 (range 270--2179) and 1077 ng/ml (range 348--3300 ng/ml) with the fixed and non-fixed combination, respectively. Even the lowest values obtained were approximately 170- and 20-fold higher than the mean half maximal inhibitory concentration (IC~50~; 1.62 ng/ml; upper 95% CI: 13.1 ng/mL) of *Plasmodium falciparum* parasites from the Thai--Burmese border, respectively \[[@CR4]\]. A note of caution should be introduced, however, when extrapolating from in vitro data to in vivo situations, particularly for the artemisinin-type compounds. While clinical failures to artemisinins are being reported from Western Cambodia \[[@CR19]\], there is no clear association with increased IC~50~s, and the in vitro test as customarily performed may not be ideal for this type of compound.

The major question, then, is whether this lack of strictly defined bioequivalence is clinically relevant in patients. Comparison with biological data indicates that these differences are not expected to alter clinical responses in patients. Indeed, looking at available clinical data, a randomised controlled trial with a non-inferiority design comparing the loose and fixed-dose combinations has found similar efficacy rates for both combinations in paediatric falciparum malaria in Burkina-Faso \[[@CR20]\]. The 80--125% limits for bioequivalence should also be based on the therapeutic window and pharmacokinetic/pharmacodynamic characteristics of a drug and should thus consider safety as well as efficacy \[[@CR17]\]. For both drugs, and particularly AQ, which may have an increased risk of toxicity with higher doses \[[@CR21], [@CR22]\], exposure with the fixed formulation is well within the upper limit of acceptance. It should also be noted that the dose of AQ in the non-fixed combination was 13% higher than that in the fixed combination owing to different tablet strengths and that the data were not normalised by body weight in these analyses.

Irrespective of the discussion concerning the bioequivalence of the fixed and non-fixed formulation of AQ and AS, this study still adds to the currently limited information on the disposition of AQ. Two recent studies have reported considerably different pharmacokinetic characteristics of AQ \[[@CR23], [@CR24]\]. These differences, however, could be ascribed to different subject populations, disease effect and analytical assays: one study measured DEAQ in children with malaria from Papua New Guinea treated with AQ (10 mg/kg) for 3 days \[[@CR23]\]; the other study investigated South African adult healthy volunteers given a single dose of AQ alone (10 mg/kg) \[[@CR24]\]. The South Africa paper also reported the effects of co-administering AS and AQ with a three-phase cross-over design. This co-administration resulted in an approximately 35% reduction of the AUC for both drugs. Exposure to AS + AQ (measured by C~max~ and AUC) in the South African volunteers was approximately one-third of that in our study. This difference does not seem to be related to the assay used, as the detection limit of the HPLC--ECD used in our study is higher than that of the liquid chromatography/mass spectrometry used in the South African study (LLOQ 20 and 5 ng/ml, respectively). One possible explanation of this observation is that polymorphisms of the CYP2C8 enzyme could contribute to different rates of drug metabolism \[[@CR25]\].

For AS + AQ and other currently available ACTs, the selection of combination treatment doses has been largely empirical, aiming to achieve the same doses as if given individually. The dose--response relationship for AS has been described \[[@CR26]\], but there is currently very little information, especially in malaria patients, on the pharmacokinetic/pharmacodynamic properties of AQ or the AS + AQ combination. A recent study exploring data from children in Zanzibar and Papua New Guinea derived the population kinetics of DEAQ and found a significant but weak correlation between the levels of DEAQ on Day 7 and antimalarial efficacy \[[@CR27]\].

In clinical trials of uncomplicated falciparum malaria, co-administration of AS + AQ has been shown to be more effective than AQ alone \[[@CR28]\] and is generally effective across Africa, although with regional variations, depending on the sensitivity of the local parasite strains to AQ \[[@CR29]\]. Since the majority of these studies were conducted with individually formulated AS and AQ, which were either the same products as those used here for reference or equivalent products, combining the two drugs into a single tablet can be expected to produce the same clinical results, given that the levels of exposure achieved in this study were similar.

With respect to AS, the main disposition parameters were similar to those of a previous study in Malaysian volunteers following a single oral dose of 200 mg \[[@CR30]\]. The AS + AQ combination was well tolerated, and only minor changes in safety parameters occurred, although the sample size was too small to detect rare events. In particular, there was no indication of liver or haematological toxicity, the two toxicities that have caused fatalities in the past when AQ was used as prophylaxis \[[@CR31]\]. Although the number of healthy subjects was limited, each was exposed twice to AQ and followed for a long time. It has been suggested that repeat exposure to AQ may favour toxicity through the formation of a quinoneimine that may lead to immunoglobulin G immune-mediated liver and neutrophil toxicity. Asymptomatic, self-resolving hepatitis was reported in a healthy female subject in the South African study \[[@CR32]\]. Clinicians should be wary of this possibility in clinical practice.

With the wider use of the new fixed-dose AS + AQ combination, further studies on the disposition of these compounds in malaria patients are warranted, and safety should continue to be monitored.
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